The 10 latest articles on Clinical Specialties & Body Systems come from 7 sources, published between Oct 14 and Nov 13. Most come from Yahoo Finance (3) and newswise.com (2).
People in these stories: Ersodetug (3), Ersodetug Ersodetug (2), Rezolute (2)
Organizations: FDA (3), Company (3), Rezolute, Inc. (2), GIR (2), ICT (2), Inc (2)
Places: HI (3), San Diego (2), U.S. (2), MD (2), REDWOOD CITY (2), Calif. (2)
This is a paid press release. Contact the press release distributor directly with any inquiries. POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms Regeneron Pharmaceuticals, Inc. Thu, November 12, 2026 at 5:00 PM EST…
This is a paid press release. Contact the press release distributor directly with any inquiries. New Research Published in Ophthalmology Shows Genetic Testing Can Help Predict Glaucoma Risk, Progression and Surgery SightScore Glaucoma Test Kit by Seonix Bio Business Wire…
Credit: Photo by Cedars-Sinai. Leo Mascarenhas, MD, MS, will serve as director of Pediatric Hematology and Oncology at Cedars-Sinai Guerin Children’s and as medical director of the Sarcoma Program at Cedars-Sinai Cancer. Newswise — LOS ANGELES (June 22, 2023) -- Leo Mascarenhas, MD, MS,…
This is a paid press release. Contact the press release distributor directly with any inquiries. Summit Health Expands Access to Coordinated Specialty Care with New Livingston Multispecialty Facility Business Wire Thu, November 12, 2026 at 9:00 AM EST 3 min read New Jersey's No.
Credit: Shutterstock. Newswise — Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will present a wide range of new breast cancer research at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting advances in early detection, precision medicine, artificial intelligence, treatment-related…
Recent Quotes My Watchlist Indicators Markets Stocks ETFs Tools Markets: Overview News Currencies International Treasuries Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer By: Genentech via Business Wire July 02, 2026 at…
After more than a decade of providing high-quality cancer and research stories via the Fred Hutch website, the organization is evolving its storytelling to go beyond the browser. David Patton, Fred Hutch's content strategy lead, talks with Heart of the…
Published on 10/14/2026 at 04:05 pm EDT Rezolute, Inc. announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026. The upLIFT study is a single-arm, open-label, registrational study in 16 participants…
PRESS RELEASE GlobeNewswire Nov. 13, 2026, 06:18 AM Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December…
By: Rezolute, Inc. via GlobeNewswire June 02, 2026 at 07:00 AM EDT ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Study now 50% enrolled 6 of 8 participants have already met…
Deep dives by specialty—organs, systems, and diseases managed by expert teams.
An article joins this feed when it matches these terms. Each one is also a search of its own.